The Beat Goes On – Emergency Treatment of Acute Decompensating Heart Failure (ADHF)
Module 2: New and Emerging Therapy for ADHF
This program is developed through a collaborative partnership between Antidote Education Company and ArcheMedX.
This CME activity is supported by an educational grant from Novartis.
Scroll to the Bottom of this Information to Begin this Course
Release date: May 5, 2017
Valid through: May 5, 2018
Topic: Heart Failure
Media: Internet/Streaming Video
Estimated Time to Complete Activity: 45 minutes
This program is designed for emergency department physicians and residents, hospitalists, cardiologists, and others involved in the care of patients with acute heart failure.
Statement of Purpose
The curriculum is intended to provide an update of the latest information and guidelines for managing acute decompensated heart failure (ADHF). A review of trial reports on new therapies will help drive healthcare providers toward best practices in effective care of patients with acute heart failure.
Upon completion of this activity, the participant should be able to:
- Evaluate the clinical trial data on the mechanisms of action, efficacy, and safety of old, new and emerging therapies for acute decompensated heart failure
- Review clinical trial results of new and emerging therapies to inform evidence-based decision making for patients with acute heart failure
- Physicians — maximum of 0.75 AMA PRA Category 1 Credits™
- Physicians — Approved for 0.75 AAFP Prescribed credits
- Nurse Practitioners — 0.75 contact hours (.15 hours pharmacology)
All other healthcare professionals completing this course will be issued a statement of participation.
Program Chair & Presenting Faculty:
James L. Januzzi, Jr., MD, FACC, FESC
Hutter Family Professor of Medicine in the Field of Cardiology,
Massachusetts General Hospital, Boston, MA;
Faculty, Harvard Clinical Research Institute, Boston, MA
Dr. James Januzzi is currently the Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine at the Massachusetts General Hospital and Hutter Family Professor of Medicine at Harvard Medical School. He is also a faculty member at the Harvard Clinical Research Institute.
Dr. Januzzi is a researcher, teacher, and active clinician. Dr. Januzzi has contributed greatly to the understanding of cardiac biomarker testing, where his work with the natriuretic peptides and troponin has set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndrome. Dr. Januzzi's research group has also pioneered first-in-human analyses of several novel biomarkers, including two with regulatory approval that are also incorporated into clinical practice guidelines (ST2 and Galectin-3). Additionally, he has performed extensive work in studies of biomarkers in acute kidney injury.
Dr. Januzzi has published more than 400 manuscripts, book chapters, and review articles, has edited two text books on cardiac biomarker testing. He is on the editorial board of numerous scientific journals, including current service as an Associate Editor at the Journal of the American College of Cardiology: Heart Failure. He was the chairman of the NT-proBNP Consensus Panel, is the lead author of the Heart Failure Section for the Universal Definition of MI Biomarker Task Force, was a section editor and member of the working group for the 2013 ACC/AHA Clinical Practice Guidelines for Heart Failure, and is on the planning committee for the 2015 Heart Failure Society of America meetings. Dr. Januzzi has won numerous awards for teaching, playing an active role for clinical trainees in cardiology and medical house staff at the MGH; additionally, Dr. Januzzi serves as a mentor for cardiology research fellows, directing the Dennis and Marilyn Barry Fellowship in Cardiovascular Research. He is a frequent speaker at scientific meetings on the local, national and international level. He is an active clinician, with a busy consultative cardiology practice, and has been the cardiology consultant to the Boston Red Sox Baseball Club since 2005.
Peter S. Pang, MD, FACEP, FAHA, FACC
Associate Professor of Emergency Medicine and an Affiliated Regenstrief Scientist,
Indiana University School of Medicine;
Director of Clinical Research,
Department of Emergency Medicine;
Chief Science Officer for Mobile Integrated Health with Indianapolis EMS,
Peter S. Pang MD MS FACEP FAHA FACC is an Associate Professor of Emergency Medicine and an Affiliated Regenstrief Scientist at the Indiana University School of Medicine. He is the Director of Clinical Research in the Department of Emergency Medicine and also the Chief Science Officer for Mobile Integrated Health with Indianapolis EMS. He recently became a Hoosier after spending 10 years at Northwestern University as Associate Chief and Associate Director of Experimental Therapeutics in the Center for Cardiovascular Innovation. Dr. Pang went to medical school at the University of Texas Health Science Center at San Antonio and then completed residency and chief residency at the Brigham and Women’s / Massachusetts General Hospital combined program in Emergency Medicine. His primary research area is acute heart failure. He has published over a hundred peer-reviewed publications and textbook chapters. He has served as a Co-Chair or steering committee member for multiple Phase II and Phase III AHF clinical trials. He is an Associate Editor of the Journal of the American College of Cardiology-Heart Failure and a member of the editorial board of the Journal of Cardiac Failure.
G. Michael Felker, MD
Professor of Medicine,
Duke University School of Medicine,
G. Michael Felker, MD, MHS, is Professor of Medicine with tenure in the Division of Cardiology at Duke University Medical Center. He is Chief of the Heart Failure Section at Duke University School of Medicine. He did his medical training at Duke University School of Medicine, his internal medicine training at Johns Hopkins Hospital where he was chief resident, and his cardiology training at Duke. Dr. Felker has published over 200 peer-reviewed articles and book chapters in the field of heart failure. He has served on the Executive and Steering Committees for multiple national and international clinical trials in heart failure. He directs the Advanced Heart Failure Fellowship Training Program at the Duke University School of Medicine. Dr Felker is an editorial board member or peer reviewer for multiple high impact medical journals, including the New England Journal of Medicine, JAMA, Lancet, Circulation, and JACC. He is the Associate Editor of JACC: Heart Failure and co-editor of Heart Failure: A Companion to Braunwald’s Heart Disease, the leading heart failure textbook. His research focus in on clinical trials in acute and chronic heart failure and the use of biomarkers as diagnostics, prognostic, and therapeutic tools in heart failure.
Michael Fleming, MD, FAAFP
Clinical Associate Professor of Family Medicine,
LSA Health Science Center,
Clinical Assistant Professor of Family and Community Medicine,
Tulane University School of Medicine,
New Orleans, LA;
Chief Medical Officer,
Antidote Education Company.
Dr. Fleming is chief medical officer for Antidote Education Company. He is a Clinical Associate Professor of Family Medicine at LSU Health Science Center in Shreveport, and Clinical Assistant Professor of Family and Community Medicine at Tulane University School of Medicine. Dr. Fleming has more than 29 years of medical field experience and is past President of the American Academy of Family Physicians and the Louisiana Academy of Family Physicians; and was founding President of the Louisiana Health Care Quality Forum.
AMA: Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Antidote designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AAFP: This Enduring Material activity, The Beat Goes On – Emergency Treatment of Acute Decompensating Heart Failure, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 04/14/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approved for 0.75 AAFP Prescribed credits
AAPA: The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.75 hours of Category 1 credit for completing this activity.
AANP: This activity is approved 0.75 contact hour(s) of continuing education (which includes 0.15 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 17042638. This activity was planned in accordance with AANP CE Standards and Policies.
Disclosures of Conflicts of Interest
Antidote is committed to creating, developing, and operating high-quality, relevant, and practical continuing medical education activities that are in compliance with the ACCME's policies on commercial support and disclosure. Specifically, we are dedicated to ensuring that our events are planned and implemented free of the control of commercial interests and to identifying and resolving conflicts of interest of all persons in a position to control the content of an educational activity before the educational activity is delivered to our attendees. In addition, it is our standard practice to disclose all relevant financial relationships of our speakers in writing to our attendees before the beginning of an educational activity.
Individuals in a position to control the content of this CME activity reported the following relevant financial relationships with commercial interests:
- Grants/Research Support: Boehringer Ingelheim, GE Healthcare, Johnson & Johnson, Merck, Novartis, Pfizer, Roche
- Consultant: Critical DX
- Grants/Research Support: Roche
- Consultant: Bristol-Myers Squibb, Novartis, Roche, Trevena, scPharmaceuticals
- Honoraria: Bristol-Myers Squibb
- Grants/Research Support: Amgen, Novartis, Otsuka
- Consultant: Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Novartis, Amgen, MyoKardia
The following individuals have indicated no conflict of interest disclosures to report:
Matthew Fleming (Vice President, Antidote Education Company)
Michael O. Fleming, MD FAAFP (Chief Medical Officer, Course Director)
Margaret V. Clark (Editor)
Method of Participation
- Read the learning objectives and faculty disclosures.
- Click on the link below to participate in the online activity. Answer any polling questions presented.
- Complete the post-test and evaluation presented at the end of the activity.
A statement of credit will be issued automatically upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. You will have 3 opportunities to successfully complete the post-test.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. This includes current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple’s Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
The material presented in this course is being made available by Antidote Education Company and ArcheMedX for educational purposes only. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations. Opinions expressed in this activity are those of the faculty and not of Antidote.
Every effort has been made to assure the accuracy of the data presented at this course. Physicians may care to check specific details such as drug doses and contraindications in standard sources prior to clinical application.
Off-Label or Investigational Product Discussion
All faculty have indicated that this enduring material does not include the off-label/investigational use of a commercial product or device.
Copyright © 2017 Antidote Education Company. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.